FOLH1 and neuroendocrine neoplasm: Examples of FDA-approved radiopharmaceuticals that are significantly improving outcomes for cancer patients include beta (β)-particle-emitting RLT LUTATHERA® (i.e., [177Lu]Lu-DOTATATE) for advanced neuroendocrine tumors (NETs) and PLUVICTO® (i.e., [177Lu]Lu-PSMA-617) for metastatic castrate-resistant prostate cancer (mCRPC) targeting somatostatin receptor type 2 (SSTR2) and prostate-specific membrane antigen (PSMA), respectively.